Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [ 18 F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Pierre VeraSébastien ThureauFlorence Le TinierPhilippe Chaumet-RiffaudSébastien HapdeyHélène Kolesnikov-GauthierEtienne MartinAlina Berriolo-RiedingerNicolas PourelJean Marc BrogliaPierre BoissellierSophie GuillemardNaji SalemIsabelle Brenot-RossiCécile Le PéchouxCéline BertholdEtienne Giroux-LeprieurDamien MoreauSophie GuillermKhadija BenaliLaurent TessonnierClarisse Audigier-ValetteDelphine LerougeElske QuakCarole MassabeauFrédéric CourbonPatricia MoissonAnne LarrouyRomain ModzelewskiPierrick GouelNadia GhazzarAlexandra LanglaisElodie AmourGérard ZalcmanPhilippe GiraudPublished in: The Lancet. Oncology (2024)
Programme Hospitalier de Recherche Clinique National 2014.